{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:43:12Z","timestamp":1788270192477,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T00:00:00Z","timestamp":1445385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s11883-015-0550-5","type":"journal-article","created":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T23:49:09Z","timestamp":1445471349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention"],"prefix":"10.1007","volume":"17","author":[{"given":"Bryan A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmaine","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,21]]},"reference":[{"key":"550_CR1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev.physiol.69.031905.160725","volume":"69","author":"DQ Wang","year":"2007","unstructured":"Wang DQ. Regulation of intestinal cholesterol absorption. Annu Rev Physiol. 2007;69:221\u201348.","journal-title":"Annu Rev Physiol"},{"key":"550_CR2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-physiol-012110-142233","volume":"73","author":"L Jia","year":"2011","unstructured":"Jia L, Betters JL, Yu L. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol. 2011;73:239\u201359.","journal-title":"Annu Rev Physiol"},{"issue":"25","key":"550_CR3","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program Expert Panel on Detection, E. and A. Treatment of High Blood Cholesterol in","year":"2002","unstructured":"National Cholesterol Education Program Expert Panel on Detection, E. and A. Treatment of High Blood Cholesterol in. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143\u2013421.","journal-title":"Circulation"},{"issue":"9753","key":"550_CR4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists, C","year":"2010","unstructured":"Cholesterol Treatment Trialists, C et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"25 Pt B","key":"550_CR5","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889\u2013934. These are the updated guidelines which many practitioners are currently incoroporating into daily practice. These cholesterol management guidelines call for the intensification of statins in many populations, and for those patients who cannot tolerate the intensified regimen, sets the stage for use of other non-statin agents to achieve LDL reduction.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"550_CR6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1056\/NEJMms1314569","volume":"370","author":"JF Keaney Jr","year":"2014","unstructured":"Keaney Jr JF, Curfman GD, Jarcho JA. A pragmatic view of the new cholesterol treatment guidelines. N Engl J Med. 2014;370(3):275\u20138.","journal-title":"N Engl J Med"},{"issue":"9493","key":"550_CR7","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267\u201378.","journal-title":"Lancet"},{"issue":"2","key":"550_CR8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ahj.2014.05.004","volume":"168","author":"MA Blazing","year":"2014","unstructured":"Blazing MA et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014;168(2):205\u201312. e1.","journal-title":"Am Heart J"},{"issue":"22","key":"550_CR9","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1056\/NEJMoa1405386","volume":"371","author":"Myocardial Infarction Genetics Consortium, I","year":"2014","unstructured":"Myocardial Infarction Genetics Consortium, I et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371(22):2072\u201382.","journal-title":"N Engl J Med"},{"issue":"5661","key":"550_CR10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","volume":"303","author":"SW Altmann","year":"2004","unstructured":"Altmann SW et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201\u20134.","journal-title":"Science"},{"issue":"4","key":"550_CR11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.amjcard.2012.11.002","volume":"111","author":"S Hayek","year":"2013","unstructured":"Hayek S et al. Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol. 2013;111(4):532\u20139.","journal-title":"Am J Cardiol"},{"issue":"2","key":"550_CR12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","volume":"223","author":"D Morrone","year":"2012","unstructured":"Morrone D et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251\u201361.","journal-title":"Atherosclerosis"},{"issue":"17","key":"550_CR13","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jacc.2007.01.067","volume":"49","author":"MH Davidson","year":"2007","unstructured":"Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol. 2007;49(17):1753\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"550_CR14","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1368-5031.2004.00289.x","volume":"58","author":"MH Davidson","year":"2004","unstructured":"Davidson MH et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004;58(8):746\u201355.","journal-title":"Int J Clin Pract"},{"issue":"8A","key":"550_CR15","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","volume":"97","author":"JM McKenney","year":"2006","unstructured":"McKenney JM et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8A):89C\u201394.","journal-title":"Am J Cardiol"},{"issue":"12","key":"550_CR16","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.amjcard.2010.01.363","volume":"105","author":"I Holme","year":"2010","unstructured":"Holme I et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am J Cardiol. 2010;105(12):1802\u20138.","journal-title":"Am J Cardiol"},{"issue":"9784","key":"550_CR17","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet"},{"issue":"1","key":"550_CR18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12933-014-0159-y","volume":"13","author":"A Tenenbaum","year":"2014","unstructured":"Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014;13(1):159.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"550_CR19","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/heartjnl-2013-304678","volume":"100","author":"M Pauriah","year":"2014","unstructured":"Pauriah M et al. High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. Heart. 2014;100(11):867\u201372. This is an important study published prior to IMPROVE-IT looking at the additive effect of ezetimibe and statin. Its conclusion was limited by the power necessary to detect a difference, and the IMPROVE-IT trial built on its convincing positive conclusion.","journal-title":"Heart"},{"issue":"25","key":"550_CR20","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. This was the important, convincing study which documented the positive additive effect of ezetimibe plus a statin in improving cardiovascular outcomes, using the gold standard RCT.","journal-title":"N Engl J Med"},{"issue":"5","key":"550_CR21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cjca.2015.03.019","volume":"31","author":"TJ Anderson","year":"2015","unstructured":"Anderson TJ. New hope for lipid-lowering beyond statins: effect of IMPROVE-IT on understanding and implementation of atherosclerosis prevention. Can J Cardiol. 2015;31(5):585\u20137. This is a followup commentary helpful in understanding how to incorporate IMPROVE-IT into clinical practice.","journal-title":"Can J Cardiol"},{"key":"550_CR22","first-page":"810","volume":"1","author":"GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto Miocardico)","year":"2000","unstructured":"GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto Miocardico). Results of the lowdose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J. 2000;1:810\u201320.","journal-title":"Ital Heart J"},{"key":"550_CR23","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998\u20133007.","journal-title":"JAMA"},{"key":"550_CR24","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","volume":"361","author":"H Holdaas","year":"2003","unstructured":"Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024\u201331.","journal-title":"Lancet"},{"key":"550_CR25","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","volume":"287","author":"PW Serruys","year":"2002","unstructured":"Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215\u201322.","journal-title":"JAMA"},{"key":"550_CR26","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615\u201322.","journal-title":"JAMA"},{"key":"550_CR27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001\u20139.","journal-title":"N Engl J Med"},{"key":"550_CR28","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","unstructured":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349\u201357.","journal-title":"N Engl J Med"},{"key":"550_CR29","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623\u201330.","journal-title":"Lancet"},{"key":"550_CR30","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149\u201358.","journal-title":"Lancet"},{"key":"550_CR31","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301\u20137.","journal-title":"N Engl J Med"},{"key":"550_CR32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199701163360301","volume":"336","author":"Post Coronary Artery Bypass Graft Trial Investigators","year":"1997","unstructured":"Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153\u201362.","journal-title":"N Engl J Med"},{"key":"550_CR33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, CARDS investigators, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo controlled trial. Lancet. 2004;364:685\u201396.","journal-title":"Lancet"},{"key":"550_CR34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7\u201322.","journal-title":"Lancet"},{"key":"550_CR35","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383\u20139.","journal-title":"Lancet"},{"key":"550_CR36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.numecd.2011.05.005","volume":"21","author":"TA Miettinen","year":"2011","unstructured":"Miettinen TA, Gylling H, Nissinen MJ. The role of serum non-cholesterol sterols as surrogate markers of absolute cholesterol synthesis and absorption. Nutr Metab Cardiovasc Dis. 2011;21:765\u20139.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"550_CR37","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1056\/NEJMoa1405386","volume":"371","author":"NO Stitziel","year":"2014","unstructured":"Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371:2072\u201382.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-015-0550-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-015-0550-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-015-0550-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T15:49:23Z","timestamp":1567266563000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-015-0550-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,21]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["550"],"URL":"https:\/\/doi.org\/10.1007\/s11883-015-0550-5","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,21]]},"article-number":"72"}}